Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2023 11:07 ET | Source: Vantage Market Research

Antibody Drug Conjugates Market Size & Share to Surpass $13.17 Billion by 2028 | Vantage Market Research

WASHINGTON, DC, April 04, 2023 (GLOBE NEWSWIRE) -- The Global Antibody Drug Conjugates (ADCS) Market is valued at USD 4.24 Billion in 2021 and is projected to attain a value of USD 13.17 Billion by...
February 15, 2022 04:39 ET | Source: Vantage Market Research

Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...
May 21, 2020 17:00 ET | Source: Option Care Health, Inc.

Option Care Health Selected as Preferred Pharmacy Partner To Prepare and Distribute Breakthrough Cancer Therapy

BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate...
June 18, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer

- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
November 30, 2015 07:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer

LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug...